Atreca, Inc. Announces Pricing of Underwritten Public Offering of Common Stock
July 16 2020 - 12:06AM
Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing
its differentiated platform to discover and develop novel
antibody-based immunotherapeutics to treat a range of solid tumor
types, today announced the pricing of its previously announced
underwritten public offering of 7,031,250 shares of its Class A
Common Stock and 781,250 shares of its Class B Common Stock (the
“Shares”), each at a price to the public of $16.00 per share. Gross
proceeds to Atreca from the offering are expected to be $125.0
million, before deducting underwriting discounts and commissions
and estimated offering expenses. In addition, Atreca has
granted the underwriters a 30-day option to purchase up to
1,171,875 additional shares of its Class A Common Stock at the
public offering price, less underwriting discounts and
commissions. The offering is expected to close on or about
July 20, 2020, subject to the satisfaction of customary closing
conditions. All of the shares are being offered by Atreca.
Cowen and Company, LLC, Evercore Group L.L.C.
and Stifel, Nicolaus & Company, Incorporated are acting as
joint book-running managers for the offering. Canaccord Genuity LLC
is acting as lead manager for the offering. Roth Capital Partners,
LLC and Brookline Capital Markets, a division of Arcadia
Securities, LLC are acting as co-managers for the offering.
A shelf registration statement relating to the
offered Shares was filed with the Securities and Exchange
Commission (SEC) on July 2, 2020, and was declared effective on
July 10, 2020. A preliminary prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and a final prospectus supplement and accompanying prospectus
related to the offering will be filed with the SEC and will be
available on the SEC’s website, located at www.sec.gov. The
offering is being made only by means of a prospectus supplement and
accompanying prospectus. Copies of the final prospectus
supplement and the accompanying prospectus related to the offering
may be obtained, when available, from Cowen and Company, LLC c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY, 11717, Attention: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926; Evercore Group L.L.C., Attention: Equity Capital Markets,
55 East 52nd Street, 36th Floor, New York, New York 10055, by email
at ecm.prospectus@evercore.com, or by telephone at (888) 474-0200;
or Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street, Suite 3700, San Francisco,
California 94104, or by telephone at 415-364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding Atreca’s expectations
regarding the completion and timing of the public offering. In some
cases, you can identify these statements by forward-looking words
such as “expect,” “will,” “may,” or the negative or plural of these
words or similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances). These
forward-looking statements are based on Atreca's expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and the satisfaction of customary closing conditions related to the
public offering. There can be no assurance that Atreca will be able
to complete the public offering on the anticipated terms, or at
all. Additional information concerning these and other risks can be
found in Atreca’s periodic filings with the SEC, including under
the heading "Risk Factors" contained therein, as well as the risks
identified in the registration statement and the preliminary
prospectus supplement relating to the offering. Any forward-looking
statements that Atreca makes in this press release speak only as of
the date of this press release. Except as required by law, Atreca
assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise,
after the date of this press release.
Atreca Contacts
Atreca, Inc. Herb Cross Chief Financial Officer info@atreca.com
Investors: Alex Gray, 650-779-9251 agray@atreca.com
Media: Sheryl Seapy, 213-262-9390 sseapy@w2ogroup.com
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Aug 2023 to Aug 2024